Beryl Drugs Receives Upgraded Stock Call from MarketsMOJO, Showing Neutral Stance on Performance

Beryl Drugs, a microcap pharmaceutical company, has recently received an upgraded stock call from MarketsMOJO. The stock has been upgraded to a 'Hold' rating, indicating a neutral stance on the company's performance.
The technical trend for Beryl Drugs has improved from Mildly Bullish to Bullish on 22-May-24, resulting in a 5.73% return since then. This is supported by multiple bullish factors such as MACD, Bollinger Band, KST, and OBV.

In terms of valuation, Beryl Drugs has an attractive ROCE of 14 and a low enterprise value to capital employed ratio of 1.7. Additionally, the stock is currently trading at a discount compared to its average historical valuations. Over the past year, the stock has generated a return of 152.86%, while its profits have risen by 94%. The PEG ratio of the company is also at a favorable 0.

The majority of shareholders in Beryl Drugs are non-institutional investors, indicating a strong market performance. The stock has outperformed the market (BSE 500) with a return of 152.86% in the last year, compared to the market's 35.99% return.

However, Beryl Drugs does have some weak fundamental strengths. Its average ROCE is at 0%, indicating poor long-term growth potential. The company's net sales have only grown at an annual rate of 14.92% and its operating profit at 1.31% over the last 5 years. Additionally, the company has a high debt to EBITDA ratio of 0 times, indicating a low ability to service debt.

In the latest quarter, Beryl Drugs' net sales have decreased by -6.47%, resulting in flat results for Dec 23. Overall, while Beryl Drugs has shown strong market performance in the past year, its long-term growth potential and debt management may be areas of concern for investors.